Scalper1 News
When the FDA last month approved the first biosimilar drug, the U.S. took its first step into a lucrative but potentially disruptive field of medicine. Pfizer (PFE), which is moving big into biosimilars with its $17 billion acquisition of Hospira (HSP), has estimated that global biosimilar sales could hit $17 billion to $20 billion a year by 2020. That’s vs. just $1 billion now, with those sales mainly in the European Union. With the Scalper1 News
Scalper1 News